Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.

"Declaration of personal interests : William J. Sandborn has received grants, personal fees and nonfinancial support from Pfizer Inc during the conduct of the study; grants and personal fees from AbbVie, Amgen, Celgene, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer Inc, Prometheus Laboratories, Robarts Clinical Trials (owned by Health Academic Research Trust or HART), Salix Pharmaceuticals, Shire and Takeda; personal fees from Allergan, Arena Pharmaceuticals, Avexegen Therapeutics, Biogen Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, Celltrion, Conatus, Cosmo Technologies, Ferring Pharmaceuticals, Forbion, Forward Pharma, Immune Pharmaceuticals, Incyte, Kyowa Hakko Kirin Pharma, Landos Biopharma, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Otsuka, Paul Hastings, Reistone, Seres Therapeutics, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma and Vivilex Pharmaceuticals; personal fees and other from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals and Vimalan Biosciences; grants from Atlantic Pharmaceuticals; and other fees from Ventyx Biosciences, all outside of the submitted work. Additionally, William J. Sandborn's spouse has received consulting fees from, and owned stock options in, Opthotech and Progenity, and has been an employee of, and owned stock options in, Escalier Biosciences, Oppilan Pharma, Precision IBD, Ventyx Biosciences and Vimalan Biosciences. Julian Panés has received consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Ferring, Genentech/Roche, GoodGut, GSK, Janssen, MSD, Nestlé, Oppilan, Pfizer Inc, Progenity, Takeda, Theravance, TiGenix and Topivert. Bruce E. Sands has received grant support, personal fees and nonfinancial support from Pfizer Inc during the conduct of this study; and personal fees from AbbVie, Akros Pharma, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, EnGene, Forward Pharma, Immune Pharmaceuticals, Ironwood Pharmaceuticals, Lycera, Lyndra, Receptos, Shire, Synergy Pharmaceuticals, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, Topivert and Salix; grants, personal fees and nonfinancial support from Celgene, Janssen and Takeda; and personal fees and nonfinancial support from 4D Pharma, Capella Bioscience, F. Hoffmann‐La Roche, Ferring, Gilead, Lilly, MedImmune, Oppilan Pharmaceuticals, Otsuka, Palatin Technologies, Prometheus Laboratories, Protagonist Therapeutics, Rheos Medicines, Seres Therapeutics, Vivelix Pharmaceuticals and UCB, all outside of the submitted work. Walter Reinisch has received research support from Abbott, AbbVie, AESCA, Centocor, Dr Falk Pharma, Immundiagnostik and MSD; lecture fees from Abbott, AbbVie, AESCA, Aptalis, Celltrion, Centocor, Danone, Dr Falk Pharma, Elan, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma, MSD, Otsuka, PDL, Pharmacosmos, Schering‐Plough, Shire, Takeda, Therakos, Vifor and Yakult; and consulting fees from Abbott, AbbVie, AESCA, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia Biologics, Bioclinica, Biogen Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Cellerix, Celltrion, Centocor, ChemoCentryx, Covance, Danone, Dr Falk Pharma, Elan, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson and Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millennium, Mitsubishi Tanabe Pharma, MSD, Nestlé, Novartis, Ocera, Otsuka, PDL, Pfizer Inc, Pharmacosmos, Procter & Gamble, Prometheus Laboratories, Robarts Clinical Trials, Schering‐Plough, Second Genome, SetPoint Medical, Takeda, Therakos, TiGenix, UCB, Vifor, Zyngenia and 4SC. Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V. Jones, Irene Modesto and Daniel Quirk are employees and stockholders of Pfizer Inc. Silvio Danese has been a speaker, consultant and advisory board member for AstraZeneca, Boehringer Ingelheim, Cosmo Pharmaceuticals, Ferring, Genentech, Grünenthal, Johnson and Johnson, Merck & Co, Millennium, Novo Nordisk, Pfizer Inc, Pharmacosmos, Takeda, TiGenix and Vifor."

"Funding information"